Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients
Metrics: PDF 592 views | HTML 1281 views | ?
Zhibo Tan1, Chao Yang2, Xiaohan Zhang2, Pingju Zheng1 and Weixi Shen1
1Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, Guangdong, PR China
2Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, Shenzhen 518110, Guangdong, PR China
Weixi Shen, email: firstname.lastname@example.org
Keywords: GLUT1, meta-analysis, overall survival, prognosis
Received: March 06, 2017 Accepted: April 15, 2017 Published: May 04, 2017
Glucose transporter 1 (GLUT1) plays an important role in the transport and metabolism of glucose in cancer cells. An increasing number of studies have explored the connection between GLUT1 expression and prognosis in non-small cell lung cancer (NSCLC), but the results have been controversial. Therefore, we conducted a meta-analysis to obtain a comprehensive evaluation of the prognostic value of GLUT1 in NSCLC. Relevant studies from PubMed, Embase, and Web of Science were searched. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the effective measures. A total of 10 studies involving 1,665 patients were included in this meta-analysis. The results showed that GLUT1 overexpression was associated with poor overall survival (HR = 2.21; 95% CI, 1.42–3.42; p < 0.001) and disease-free survival (HR = 1.73; 95% CI, 1.35–2.23; p < 0.001). Furthermore, elevated GLUT1 expression correlated with sex (OR = 2.29; 95% CI, 1.17–4.49; p = 0.015), advanced tumor stage (OR = 2.46; 95% CI, 1.79–3.38; p < 0.001), histology (OR = 6.99; 95% CI, 4.71–10.38; p < 0.001), and large tumor size (OR = 2.77; 95% CI, 1.73–4.44; p < 0.001). This meta-analysis revealed overexpression of GLUT1 to be a biomarker of worse prognosis in NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.